Intellectual Property
June 20, 2012
|
June 19, 2012
|
June 18, 2012
|
May 29, 2012
|
Key Documents
Letters, Testimony & Comments
June 7 2013
BIO applauds the government of Brazil for taking steps towards developing regulatory requirements to ensure patients suffering from rare diseases have access to treatment.
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products. Peru is a growing market for biotechnology products and with the implementation of the US-Peru TPA, it promises to become an even bigger market.
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of biological origin. Many elements of the third draft appear to have addressed BIO's previous comments with respect to clarity of structure and definitions of terms, as well as expectations for data requirements.
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.
February 1 2013
BIO commends the INPI for their efforts to devise guidelines for examining biotechnology related inventions. Given the technological advances and the innovation that spurs it are the primary drivers of economic growth in the modern era, it is critical that patent laws and practices properly motivate and reward innovation.
Want to learn more about the biotech industry?
Business Solutions Sponsor
